CORDIS
EU research results

CORDIS

English EN

Translational research in Europe - Assessment and treatment of neuromuscular diseases

Project information

Grant agreement ID: 36825

  • Start date

    1 January 2007

  • End date

    31 December 2011

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 20 000 000

  • EU contribution

    € 10 000 000

Coordinated by:

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom

Objective

TREAT-NMD is a European neuromuscular network addressing the fragmentation currently hindering translational research for cutting edge therapies in rare neuromuscular diseases (NMD). It will strengthen European excellence in the treatment of rare NMD. Bringing promising cutting edge therapies into clinical settings is currently delayed by the lack of standardised protocols for preclinical animal studies, molecular diagnoses and patient assessment and management. TREAT-NMD will address this fragmentation by establishing a common road map for the progression of cutting edge therapies from laboratory to clinic, from the assessment of cellular and animal models, via issues of delivery, production and toxicology, to clinical outcome measures. This will be underpinned by the integration and establishment of pan-European patient databases and biobanks. The TREAT-NMD coordination centre (TNCC) will develop and integrate organisations and networks comprising the top researchers, clinicians and industries working in Europe (representing 11 countries) in partnership with patient organisations in order to deliver the dream of treatments for these devastating disorders.

Technological, educational and communication Centres of Excellence will be generated as a durable resource co-ordinated by the TNCC, which will establish Europe as the leader in translational research in this area. A strong educational programme will provide the next generation of experts with the necessary background and expertise to maintain this leading position, and integrate the voices of patient organisations in the development of future research plans. Cutting edge treatments currently under development for muscular dystrophies and spinal muscular atrophy will be specifically targeted in this process, while future developments will also benefit from the durable infrastructure of the TNCC, which will act as the portal for future pharmaceutical developments in this field.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITY OF NEWCASTLE UPON TYNE

Address

6 Kensington Terrace
Newcastle Upon Tyne

United Kingdom

Participants (26)

LEIDEN UNIVERSITY MEDICAL CENTER

Netherlands

MUSKELDYSTROPHIE-NETZWERK E.V.

Germany

FODOR JOZSEF NATIONAL CENTER FOR PUBLIC HEALTH

Hungary

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EUROPEAN NEUROMUSCULAR CENTRE

Netherlands

SUMMIT CORPORATION PLC

United Kingdom

ASSOCIATION FRANÇAISE CONTRE LES MYOPATHIES

France

UNIVERSITY OF BASEL

Switzerland

EUROPEAN ORGANISATION FOR RARE DISEASES

France

KAROLINSKA INSTITUTET

Sweden

KING'S COLLEGE LONDON

United Kingdom

SANTHERA PHARMACEUTICALS (SWITZERLAND) LTD

Switzerland

HELSINGIN YLIOPISTO

Finland

MEDICAL RESEARCH COUNCIL

United Kingdom

FONDAZIONE TELETHON

Italy

UNIVERSITÉ CATHOLIQUE DE LOUVAIN

Belgium

GENOSAFE SAS

France

ACIES

France

NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH

Hungary

UNIVERSITY COLLEGE LONDON

United Kingdom

GENETHON

France

NOVAMEN

France

UNIVERSITAETSKLINIKUM FREIBURG

Germany

LUDWIG-MAXIMILIANS-UNIVERSITÄT-MÜNCHEN

Germany

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

UNIVERSITAT AUTONOMA DE BARCELONA

Spain

Project information

Grant agreement ID: 36825

  • Start date

    1 January 2007

  • End date

    31 December 2011

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 20 000 000

  • EU contribution

    € 10 000 000

Coordinated by:

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom